1. Home
  2. MRK vs GILD Comparison

MRK vs GILD Comparison

Compare MRK & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merck & Company Inc. (new)

MRK

Merck & Company Inc. (new)

HOLD

Current Price

$115.44

Market Cap

268.7B

Sector

Health Care

ML Signal

HOLD

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

HOLD

Current Price

$138.51

Market Cap

173.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRK
GILD
Founded
2000
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
268.7B
173.9B
IPO Year
1994
2001

Fundamental Metrics

Financial Performance
Metric
MRK
GILD
Price
$115.44
$138.51
Analyst Decision
Buy
Strong Buy
Analyst Count
17
18
Target Price
$125.59
$148.39
AVG Volume (30 Days)
6.7M
4.9M
Earning Date
04-30-2026
04-24-2026
Dividend Yield
2.88%
2.35%
EPS Growth
8.01
1684.21
EPS
7.28
6.78
Revenue
$65,011,000,000.00
$24,689,000,000.00
Revenue This Year
$3.73
$4.65
Revenue Next Year
$5.42
$5.96
P/E Ratio
$16.23
$20.62
Revenue Growth
1.31
9.98
52 Week Low
$75.40
$95.30
52 Week High
$125.14
$157.29

Technical Indicators

Market Signals
Indicator
MRK
GILD
Relative Strength Index (RSI) 40.19 44.68
Support Level $113.27 $133.89
Resistance Level $124.57 $142.33
Average True Range (ATR) 2.85 3.27
MACD -0.44 0.21
Stochastic Oscillator 7.86 50.88

Price Performance

Historical Comparison
MRK
GILD

About MRK Merck & Company Inc. (new)

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: